4A3 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Immatics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.50 |
| 52 Week High | US$12.90 |
| 52 Week Low | US$6.39 |
| Beta | 0.74 |
| 1 Month Change | -10.54% |
| 3 Month Change | -39.30% |
| 1 Year Change | -24.74% |
| 3 Year Change | -44.77% |
| 5 Year Change | n/a |
| Change since IPO | -38.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4A3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.6% | -2.6% | -2.0% |
| 1Y | -24.7% | -13.2% | 6.8% |
Return vs Industry: 4A3 underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 4A3 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 4A3 volatility | |
|---|---|
| 4A3 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4A3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4A3's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 572 | Harpreet Singh | www.immatics.com |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.
Immatics N.V. Fundamentals Summary
| 4A3 fundamental statistics | |
|---|---|
| Market cap | €785.62m |
| Earnings (TTM) | -€55.79m |
| Revenue (TTM) | €115.50m |
7.0x
P/S Ratio-14.5x
P/E RatioIs 4A3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4A3 income statement (TTM) | |
|---|---|
| Revenue | €115.50m |
| Cost of Revenue | €139.50m |
| Gross Profit | -€23.99m |
| Other Expenses | €31.80m |
| Earnings | -€55.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | -20.77% |
| Net Profit Margin | -48.30% |
| Debt/Equity Ratio | 0% |
How did 4A3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:44 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immatics N.V. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |